Sanaria Inc. and the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant

18-Jun-2012 - Sanaria Inc and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the ...

Initial Trial of Sanaria's Malaria Vaccine Yields Positive Results

Findings Provide Evidence that Vaccine is Safe and Potent

09-Sep-2011 - Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria® PfSPZ Vaccine are published in Science."This is the first indication that a highly effective malaria vaccine may be available that can be used to eliminate ...

Sanaria Inc. Receives U.S. NIH Phase II Small Business Innovation Research Grant for its Malaria Vaccine Manufacturing Process

17-Sep-2009 - Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years isUS$1.99 million. Subject to satisfactory ...